Related Experiment Video
Updated: Mar 5, 2026
Purification and Visualization of Influenza A Viral Ribonucleoprotein Complexes
Published on: February 9, 2009
A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography
Yu-Fen Tseng1, Tsai-Chuan Weng2, Chia-Chun Lai2
1National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan; Institute of Molecular and Cellular Biology, National Tsing Hua University, No. 101, Section 2, Kuang Fu Road, Hsinchu 300, Taiwan.
A new purification platform enhances cell-based influenza vaccine production. This efficient process uses flow-through chromatography and filtration, yielding high-quality vaccine bulks suitable for human use.
Area of Science:
- Biotechnology
- Vaccinology
- Virology
Background:
- Emerging influenza viruses necessitate rapid, scalable vaccine production methods.
- Cell-based influenza vaccine production offers advantages over traditional methods.
- Efficient purification is critical for developing safe and effective pandemic influenza vaccines.
Purpose of the Study:
- To develop and validate an efficient purification platform for cell-based influenza vaccines.
- To streamline the process from harvest to purified bulk vaccine.
- To ensure the platform's robustness across different virus strains and cell culture systems.
Main Methods:
- A multi-step purification process involving depth filtration, formaldehyde inactivation, microfiltration, and ultrafiltration.
- Utilized anion-exchange and ligand-core chromatography without virus capture steps.
- Employed sterile filtration for the final purified bulk vaccine.
Main Results:
- Achieved 33-46% hemagglutinin (HA) recovery yields across various influenza strains and cell types.
- Demonstrated high removal rates: over 96.1% for protein and 99.7% for DNA.
- Obtained low residual cellular DNA concentrations (30-130 pg/human dose), meeting regulatory standards.
Conclusions:
- The proposed purification platform is efficient and robust for cell-based influenza vaccine production.
- The platform consistently delivers high-purity vaccine bulks meeting regulatory requirements.
- This approach offers a scalable and adaptable solution for pandemic influenza vaccine manufacturing.
